Search research articles
Contact Us
Filters
Showing results (231-240 of 251) with videos related to
Page
of 26
Sort By:
Arthritis and Rheumatism
|
February 20, 1999
Dose-loading with hydroxychloroquine improves the rate of response in early, active rheumatoid arthritis: a randomized, double-blind six-week trial with eighteen-week extension
D E Furst, H Lindsley, B Baethge, et al.
Arthritis and Rheumatism
|
October 19, 1999
The Prosorba column for treatment of refractory rheumatoid arthritis: a randomized, double-blind, sham-controlled trial
D T Felson, M P LaValley, A R Baldassare, et al.
Arthritis and Rheumatism
|
November 11, 1999
Correlates of the disability index of the health assessment questionnaire: a measure of functional impairment in systemic sclerosis
P J Clements, W K Wong, E L Hurwitz, et al.
Arthritis and Rheumatism
|
June 12, 1999
High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial
P J Clements, D E Furst, W K Wong, et al.
Rheumatology (Oxford, England)
|
June 27, 2001
Effects of the American College of Rheumatology systemic sclerosis trial guidelines on the nature of systemic sclerosis patients entering a clinical trial
D E Furst, P J Clements, W K Wong, et al.
Arthritis and Rheumatism
|
November 18, 2000
Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial
P J Clements, E L Hurwitz, W K Wong, et al.
Arthritis and Rheumatism
|
March 27, 2001
The Disability Index of the Health Assessment Questionnaire is a predictor and correlate of outcome in the high-dose versus low-dose penicillamine in systemic sclerosis trial
P J Clements, W K Wong, E L Hurwitz, et al.
Annals of Internal Medicine
|
June 3, 2000
Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo-controlled trial
J R Seibold, J H Korn, R Simms, et al.
Annals of the Rheumatic Diseases
|
March 31, 2012
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011
D E Furst, E C Keystone, J Braun, et al.
Annals of the Rheumatic Diseases
|
February 23, 2011
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
D E Furst, E C Keystone, J Braun, et al.
Page
of 26
Search research articles
Search
Showing results (231-240 of 251) with videos related to
Sort By:
Page
of 26
Arthritis and Rheumatism
|
February 20, 1999
Dose-loading with hydroxychloroquine improves the rate of response in early, active rheumatoid arthritis: a randomized, double-blind six-week trial with eighteen-week extension
D E Furst, H Lindsley, B Baethge, et al.
Arthritis and Rheumatism
|
October 19, 1999
The Prosorba column for treatment of refractory rheumatoid arthritis: a randomized, double-blind, sham-controlled trial
D T Felson, M P LaValley, A R Baldassare, et al.
Arthritis and Rheumatism
|
November 11, 1999
Correlates of the disability index of the health assessment questionnaire: a measure of functional impairment in systemic sclerosis
P J Clements, W K Wong, E L Hurwitz, et al.
Arthritis and Rheumatism
|
June 12, 1999
High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial
P J Clements, D E Furst, W K Wong, et al.
Rheumatology (Oxford, England)
|
June 27, 2001
Effects of the American College of Rheumatology systemic sclerosis trial guidelines on the nature of systemic sclerosis patients entering a clinical trial
D E Furst, P J Clements, W K Wong, et al.
Arthritis and Rheumatism
|
November 18, 2000
Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial
P J Clements, E L Hurwitz, W K Wong, et al.
Arthritis and Rheumatism
|
March 27, 2001
The Disability Index of the Health Assessment Questionnaire is a predictor and correlate of outcome in the high-dose versus low-dose penicillamine in systemic sclerosis trial
P J Clements, W K Wong, E L Hurwitz, et al.
Annals of Internal Medicine
|
June 3, 2000
Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo-controlled trial
J R Seibold, J H Korn, R Simms, et al.
Annals of the Rheumatic Diseases
|
March 31, 2012
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011
D E Furst, E C Keystone, J Braun, et al.
Annals of the Rheumatic Diseases
|
February 23, 2011
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
D E Furst, E C Keystone, J Braun, et al.
Page
of 26